New Zealand Formulary
Menu Close Menu

Fewer cancers.
Better survival.
Equity for all.

Systemic Anti-Cancer Therapy Regimen Library

Home > Leukaemias

Leukaemias Regimens


Haematology regimens within the SACT Regimen Library currently only specify mandatory supportive care medicines to be used for all patients, unless contraindicated. A clinically equivalent mandatory medicine may be substituted as per institutional practice.

Supportive care factors are included in all regimens, with the appropriate dimensions (value) as Recommended (for most patients), Consider (for some patients after clinical risk assessment), or with guidance (e.g. emetogenicity classification or if variable). Centres are expected to include antiemetics and other supportive care medicines within their own prescribing systems.


Acute lymphoblastic Regimens


Published

Name Sort
Id Sort
Version Sort
Date Sort
LEU ALL precursor B-cell - blinatumomab [CNS1 and CNS2]
312041000210100
1.0.0
18/03/2024
LEU ALL precursor B-cell - blinatumomab [CNS3]
312031000210108
1.0.0
18/03/2024
LEU ALL precursor B-cell Relapsed/Refractory - inotuzumab ozogamicin
components ▾
506411000210108
1.0.0
06/05/2025
Cycle 1, and subsequent cycles for patients who achieved CR or CRi
506421000210103
0.0.16
Cycle 1, and subsequent cycles for patients who do not achieve CR or CRi
506431000210101
0.0.21

AALL1131 Regimens


Published

Name Sort
Id Sort
Version Sort
Date Sort
LEU ALL precursor B-cell - AALL1131 [very high risk]
components ▾
392831000210102
2.0.0
03/04/2025
AALL1131 [very high risk] - Induction for CNS 1+
392841000210105
0.0.9
AALL1131 [very high risk] - Induction for CNS 2+
392851000210108
0.0.7
AALL1131 [very high risk] - Induction for CNS 3+
392861000210106
0.0.6
AALL1131 [very high risk] - Consolidation for CNS 1/2+
392871000210100
0.0.11
AALL1131 [very high risk] - Consolidation for CNS 3+
392881000210103
0.0.10
AALL1131 [very high risk] - Interim maintenance 1
392891000210101
0.0.16
AALL1131 [very high risk] - Delayed intensification
392901000210100
0.0.13
AALL1131 [very high risk] - Interim maintenance 2
392911000210103
0.0.9
AALL1131 [very high risk] - Maintenance for CNS 1/2+
392921000210108
0.0.10
AALL1131 [very high risk] - Maintenance for CNS 3+
392931000210105
0.0.10
LEU ALL precursor B-cell BCR-ABL1+ - modified AALL1131 with daSATinib
components ▾
497271000210108
1.0.0
23/03/2025
mAALL1131 with daSATinib - Induction for CNS 1+
497281000210105
0.0.14
mAALL1131 with daSATinib - Induction for CNS 2+
497291000210107
0.0.14
mAALL1131 with daSATinib - Induction for CNS 3+
497301000210106
0.0.12
mAALL1131 with daSATinib - Consolidation for CNS 1/2+
497311000210108
0.0.21
mAALL1131 with daSATinib - Consolidation for CNS 3+
497321000210103
0.0.17
mAALL1131 with daSATinib - Interim maintenance 1
497331000210101
0.0.8
mAALL1131 with daSATinib - Delayed intensification
497341000210109
0.0.23
mAALL1131 with daSATinib - Interim maintenance 2
497351000210107
0.0.12
mAALL1131 with daSATinib - Maintenance for CNS 1/2+
497361000210105
0.0.16
mAALL1131 with daSATinib - Maintenance for CNS 3+
497371000210104
0.0.15
LEU ALL precursor B-cell BCR-ABL1+ - modified AALL1131 with imatinib
components ▾
506141000210101
1.0.0
23/03/2025
mAALL1131 with imatinib - Induction for CNS1+
506151000210103
0.0.34
mAALL1131 with imatinib - Induction for CNS2+
506161000210100
0.0.28
mAALL1131 with imatinib - Induction for CNS3+
506171000210106
0.0.23
mAALL1131 with imatinib - Consolidation for CNS1/2+
506181000210108
0.0.35
mAALL1131 with imatinib - Consolidation for CNS3+
506191000210105
0.0.14
mAALL1131 with imatinib - Interim maintenance 1
506201000210107
0.0.33
mAALL1131 with imatinib - Delayed intensification
506211000210109
0.0.28
mAALL1131 with imatinib - Interim maintenance 2
506221000210104
0.0.31
mAALL1131 with imatinib - Maintenance for CNS 1/2+
506231000210102
0.0.30
mAALL1131 with imatinib - Maintenance for CNS 3+
506241000210105
0.0.21

GMALL Regimens


Published

Name Sort
Id Sort
Version Sort
Date Sort
LEU ALL precursor T-cell - GMALL T-LBL 1/2004 [55 years and under]
components ▾
392561000210108
1.0.0
20/05/2024
GMALL T-LBL 1/2004 [55 years and under] - Pre-phase and Induction I and II
392571000210102
0.0.13
GMALL T-LBL 1/2004 [55 years and under] - Consolidation I
392581000210100
0.0.12
GMALL T-LBL 1/2004 [55 years and under] - HDMTX/ASP
392591000210103
0.0.10
GMALL T-LBL 1/2004 [55 years and under] - Reinduction I and II
392521000210101
0.0.11
GMALL T-LBL 1/2004 [55 years and under] - VM26/ARAC
392531000210104
0.0.5
GMALL T-LBL 1/2004 [55 years and under] - CYCLO/ARAC
392541000210107
0.0.6
GMALL T-LBL 1/2004 [55 years and under] - Intrathecal Triple Prophylaxis
392551000210105
0.0.7
LEU ALL precursor T-cell - GMALL T-LBL 1/2004 [over 55 years]
components ▾
392481000210101
1.0.0
20/05/2024
GMALL T-LBL 1/2004 [over 55 years] - Pre-phase and Induction I and II
392491000210104
0.0.4
GMALL T-LBL 1/2004 [over 55 years] - Consolidation I
392501000210109
0.0.4
GMALL T-LBL 1/2004 [over 55 years] - HDMTX/ASP
392511000210106
0.0.2
GMALL T-LBL 1/2004 [over 55 years] - Reinduction I and II
392521000210101
0.0.11
GMALL T-LBL 1/2004 [over 55 years] - VM26/ARAC
392531000210104
0.0.5
GMALL T-LBL 1/2004 [over 55 years] - CYCLO/ARAC
392541000210107
0.0.6
GMALL T-LBL 1/2004 [over 55 years] - Intrathecal Triple Prophylaxis
392551000210105
0.0.7

HyperCVAD Regimens


Published

Name Sort
Id Sort
Version Sort
Date Sort
LEU ALL - HyperCVAD Part A and B followed by POMP Maintenance [60 years and under]
components ▾
312321000210108
1.0.0
02/04/2024
HyperCVAD [60 years and under] - Part A with CNS prophylaxis for Unknown Risk [default]
312331000210105
0.0.31
HyperCVAD [60 years and under] - Part A with CNS prophylaxis for High Risk
312341000210102
0.0.10
HyperCVAD [60 years and under] - Part B with CNS prophylaxis for Unknown Risk [default]
312351000210104
0.0.28
HyperCVAD [60 years and under] - Part B with CNS prophylaxis for High Risk
312361000210101
0.0.14
POMP Maintenance
312311000210103
0.0.13
LEU ALL - HyperCVAD Part A and B followed by POMP Maintenance [over 60 years]
components ▾
312261000210109
1.0.0
02/04/2024
HyperCVAD [over 60 years] - Part A with CNS prophylaxis for Unknown Risk [default]
312271000210103
0.0.3
HyperCVAD [over 60 years] - Part A with CNS prophylaxis for High Risk
312281000210101
0.0.2
HyperCVAD [over 60 years] - Part B with CNS prophylaxis for Unknown risk [default]
312291000210104
0.0.13
HyperCVAD [over 60 years] - Part B with CNS prophylaxis for High Risk
312301000210100
0.0.7
POMP Maintenance
312311000210103
0.0.13
LEU ALL - HyperCVAD with pegaspargase Part A and B followed by POMP Maintenance [under 40 years]
components ▾
392431000210100
1.0.0
20/05/2024
HyperCVAD with pegaspargase [under 40 years] - Part A with CNS prophylaxis for Unknown Risk [default]
392441000210108
0.0.3
HyperCVAD with pegaspargase [under 40 years] - Part A with CNS prophylaxis for High Risk
392451000210106
0.0.3
HyperCVAD with pegaspargase [under 40 years] - Part B with CNS prophylaxis for Unknown Risk [default]
392461000210109
0.0.11
HyperCVAD with pegaspargase [under 40 years] - Part B with CNS prophylaxis for High Risk
392471000210103
0.0.3
POMP Maintenance
312311000210103
0.0.13
LEU ALL precursor B-cell - HyperCVAD with RITUximab and pegaspargase Part A and B followed by POMP Maintenance [under 40 years]
components ▾
506471000210104
1.0.0
24/06/2025
HyperCVAD with RITUximab and pegaspargase [under 40 years] - Part A with CNS prophylaxis for Unknown Risk [default]
506481000210102
0.0.11
HyperCVAD with RITUximab and pegaspargase [under 40 years] - Part A with CNS prophylaxis for High Risk
506491000210100
0.0.9
HyperCVAD with RITUximab and pegaspargase [under 40 years] - Part B with CNS prophylaxis for Unknown Risk [default]
506501000210105
0.0.10
HyperCVAD with RITUximab and pegaspargase [under 40 years] - Part B with CNS prophylaxis for High Risk
506511000210107
0.0.9
POMP Maintenance
312311000210103
0.0.13
LEU ALL precursor B-cell - HyperCVAD with RITUximab Part A and B followed by POMP Maintenance [60 years and under]
components ▾
392301000210101
1.0.0
13/05/2024
HyperCVAD with RITUximab [60 years and under] - Part A with CNS prophylaxis for Unknown Risk [default]
392311000210104
0.0.19
HyperCVAD with RITUximab [60 years and under] - Part A with CNS prophylaxis for High risk
392321000210109
0.0.12
HyperCVAD with RITUximab [60 years and under] - Part B with CNS prophylaxis for Unknown Risk [default]
392331000210106
0.0.25
HyperCVAD with RITUximab [60 years and under] - Part B with CNS prophylaxis for High Risk
392341000210103
0.0.13
POMP Maintenance
312311000210103
0.0.13
LEU ALL precursor B-cell - HyperCVAD with RITUximab Part A and B followed by POMP Maintenance [over 60 years]
components ▾
391921000210100
1.0.0
13/05/2024
HyperCVAD with RITUximab [over 60 years] - Part A with CNS prophylaxis for Unknown Risk [default]
391931000210103
0.0.2
HyperCVAD with RITUximab [over 60 years] - Part A with CNS prophylaxis for High Risk
391941000210106
0.0.3
HyperCVAD with RITUximab [over 60 years] - Part B with CNS prophylaxis for Unknown Risk [default]
392281000210102
0.0.17
HyperCVAD with RITUximab [over 60 years] - Part B with CNS prophylaxis for High Risk
392291000210100
0.0.11
POMP Maintenance
312311000210103
0.0.13
LEU ALL precursor B-cell BCR-ABL1+ - HyperCVAD with daSATinib Part A and B followed by Maintenance [60 years and under]
components ▾
392681000210104
1.0.0
10/06/2024
HyperCVAD with daSATinib [60 years and under] - Part A with CNS prophylaxis for Unknown Risk [default]
392631000210103
0.0.15
HyperCVAD with daSATinib [60 years and under] - Part A with CNS prophylaxis for High Risk
392641000210106
0.0.8
HyperCVAD with daSATinib [60 years and under] - Part B with CNS prophylaxis for Unknown Risk [default]
392691000210102
0.0.14
HyperCVAD with daSATinib [60 years and under] - Part B with CNS prophylaxis for High Risk
392701000210102
0.0.16
HyperCVAD with daSATinib maintenance
392671000210101
0.0.19
LEU ALL precursor B-cell BCR-ABL1+ - HyperCVAD with daSATinib Part A and B followed by Maintenance [over 60 years]
components ▾
392621000210100
1.0.0
10/06/2024
HyperCVAD with daSATinib [over 60 years] - Part A with CNS prophylaxis for Unknown Risk [default]
392631000210103
0.0.15
HyperCVAD with daSATinib [over 60 years] - Part A with CNS prophylaxis for High Risk
392641000210106
0.0.8
HyperCVAD with daSATinib [over 60 years] - Part B with CNS prophylaxis for Unknown Risk [default]
392651000210109
0.0.10
HyperCVAD with daSATinib [over 60 years] - Part B with CNS prophylaxis for High Risk
392661000210107
0.0.9
HyperCVAD with daSATinib maintenance
392671000210101
0.0.19
LEU ALL precursor B-cell BCR-ABL1+ - HyperCVAD with RITUximab and daSATinib Part A and B followed by Maintenance [60 years and under]
components ▾
392711000210100
1.0.0
10/06/2024
HyperCVAD with RITUximab and daSATinib [60 years and under] - Part A with CNS prophylaxis for Unknown Risk [default]
392721000210105
0.0.22
HyperCVAD with RITUximab and daSATinib [60 years and under] - Part A with CNS prophylaxis for High Risk
392731000210107
0.0.16
HyperCVAD with RITUximab and daSATinib [60 years and under] - Part B with CNS prophylaxis for Unknown Risk [default]
392741000210104
0.0.39
HyperCVAD with RITUximab and daSATinib [60 years and under] - Part B with CNS prophylaxis for High Risk
392751000210101
0.0.22
Maintenance with daSATinib
392671000210101
0.0.19
LEU ALL precursor B-cell BCR-ABL1+ - HyperCVAD with RITUximab and daSATinib Part A and B followed by Maintenance [over 60 years]
components ▾
392761000210103
1.0.0
10/06/2024
HyperCVAD with RITUximab and daSATinib [over 60 years] - Part A with CNS prophylaxis for Unknown Risk [default]
392721000210105
0.0.22
HyperCVAD with RITUximab and daSATinib [over 60 years] - Part A with CNS prophylaxis for High Risk
392731000210107
0.0.16
HyperCVAD with RITUximab and daSATinib [over 60 years] - Part B with CNS prophylaxis for Unknown Risk [default]
392771000210109
0.0.26
HyperCVAD with RITUximab and daSATinib [over 60 years] - Part B with CNS prophylaxis for High Risk
392811000210109
0.0.19
Maintenance with daSATinib
392671000210101
0.0.19

UKALL14 Regimens


Published

Name Sort
Id Sort
Version Sort
Date Sort
LEU ALL - UKALL14 [40 years and under]
components ▾
391821000210109
1.0.0
02/05/2024
Steroid pre-phase
311231000210106
0.0.5
UKALL14 [40 years and under] - Phase 1 Induction
391831000210106
0.0.12
UKALL14 [40 years and under] - Phase 2 Induction
312501000210108
0.0.8
UKALL14 [40 years and under] - Intensification/CNS prophylaxis
391841000210103
0.0.31
UKALL14 [40 years and under] - Consolidation [Cycle 1]
391851000210100
0.0.2
UKALL14 [40 years and under] - Consolidation [Cycle 2]
312531000210103
0.0.8
UKALL14 [40 years and under] - Consolidation/delayed intensification [Cycle 3]
391861000210102
0.0.1
UKALL14 [40 years and under] - Consolidation [Cycle 4]
312551000210109
0.0.10
UKALL14 [40 years and under] - Maintenance
312561000210107
0.0.12
LEU ALL - UKALL14 [over 40 years]
components ▾
312481000210100
1.0.0
23/04/2024
Steroid pre-phase
311231000210106
0.0.5
UKALL14 [over 40 years] - Phase 1 Induction
312491000210103
0.0.9
UKALL14 [over 40 years] - Phase 2 Induction
312501000210108
0.0.8
UKALL14 [over 40 years] - Intensification/CNS prophylaxis
312511000210105
0.0.4
UKALL14 [over 40 years] - Consolidation [Cycle 1]
312521000210100
0.0.23
UKALL14 [over 40 years] - Consolidation [Cycle 2]
312531000210103
0.0.8
UKALL14 [over 40 years] - Consolidation/delayed intensification [Cycle 3]
312541000210106
0.0.23
UKALL14 [over 40 years] - Consolidation [Cycle 4]
312551000210109
0.0.10
UKALL14 [over 40 years] - Maintenance
312561000210107
0.0.12
LEU ALL precursor B-cell - UKALL14 with RITUximab [40 years and under] [for transplant]
components ▾
391871000210108
1.0.0
02/05/2024
Steroid pre-phase
311231000210106
0.0.5
UKALL14 with RITUximab [40 years and under] [for transplant] - Phase 1 Induction
391881000210105
0.0.7
UKALL14 with RITUximab [40 years and under] [for transplant] - Phase 2 Induction
391771000210104
0.0.2
UKALL14 with RITUximab [40 years and under] [for transplant] - Intensification/CNS prophylaxis
391891000210107
0.0.6
UKALL14 with RITUximab [40 years and under] [for transplant] - Consolidation [Cycles 1 and 2]
391901000210108
0.0.5
UKALL14 with RITUximab [40 years and under] [for transplant] - Consolidation/delayed intensification [Cycle 3]
391911000210105
0.0.9
UKALL14 with RITUximab [40 years and under] [for transplant] - Consolidation [Cycle 4]
391811000210104
0.0.1
LEU ALL precursor B-cell - UKALL14 with RITUximab [40 years and under] [not for transplant]
components ▾
392351000210100
1.0.0
16/05/2024
Steroid pre-phase
311231000210106
0.0.5
UKALL14 with RITUximab [40 years and under] [not for transplant] - Phase 1 Induction
391881000210105
0.0.7
UKALL14 with RITUximab [40 years and under] [not for transplant] - Phase 2 Induction
392361000210102
0.0.2
UKALL14 with RITUximab [40 years and under] [not for transplant] - Intensification/CNS prophylaxis
392371000210108
0.0.12
UKALL14 with RITUximab [40 years and under] [not for transplant] - Consolidation [Cycles 1 and 2]
391901000210108
0.0.5
UKALL14 with RITUximab [40 years and under] [not for transplant] - Consolidation/delayed intensification [Cycle 3]
392381000210105
0.0.8
UKALL14 with RITUximab [40 years and under] [not for transplant] - Consolidation [Cycle 4]
391811000210104
0.0.1
UKALL14 with RITUximab [40 years and under] [not for transplant] - Maintenance
392391000210107
0.0.9
LEU ALL precursor B-cell - UKALL14 with RITUximab [over 40 years] [for transplant]
components ▾
391751000210107
1.0.0
02/05/2024
Steroid pre-phase
311231000210106
0.0.5
UKALL14 with RITUximab [over 40 years] [for transplant] - Phase 1 Induction
391761000210105
0.0.9
UKALL14 with RITUximab [over 40 years] [for transplant] - Phase 2 Induction
391771000210104
0.0.2
UKALL14 with RITUximab [over 40 years] [for transplant] - Intensification/CNS prophylaxis
391781000210102
0.0.2
UKALL14 with RITUximab [over 40 years] [for transplant] - Consolidation [Cycles 1 and 2]
391791000210100
0.0.3
UKALL14 with RITUximab [over 40 years] [for transplant] - Consolidation/delayed intensification [Cycle 3]
391801000210101
0.0.4
UKALL14 with RITUximab [over 40 years] [for transplant] - Consolidation [Cycle 4]
391811000210104
0.0.1
LEU ALL precursor B-cell - UKALL14 with RITUximab [over 40 years] [not for transplant]
components ▾
392401000210105
1.0.0
16/05/2024
Steroid pre-phase
311231000210106
0.0.5
UKALL14 with RITUximab [over 40 years] [not for transplant] - Phase 1 Induction
391761000210105
0.0.9
UKALL14 with RITUximab [over 40 years] [not for transplant] - Phase 2 Induction
392361000210102
0.0.2
UKALL14 with RITUximab [over 40 years] [not for transplant] - Intensification/CNS prophylaxis
392411000210107
0.0.2
UKALL14 with RITUximab [over 40 years] [not for transplant] - Consolidation [Cycles 1 and 2]
391791000210100
0.0.3
UKALL14 with RITUximab [over 40 years] [not for transplant] - Consolidation/delayed intensification [Cycle 3]
392421000210102
0.0.3
UKALL14 with RITUximab [over 40 years] [not for transplant] - Consolidation [Cycle 4]
391811000210104
0.0.1
UKALL14 with RITUximab [over 40 years] [not for transplant] - Maintenance
392391000210107
0.0.9
LEU ALL precursor B-cell BCR-ABL1+ - UKALL14 with daSATinib
components ▾
311471000210109
1.0.0
15/01/2024
Steroid pre-phase
311231000210106
0.0.5
UKALL14 with daSATinib - Phase 1 Induction
311481000210106
0.0.2
UKALL14 with daSATinib - Phase 2 Induction
311491000210108
0.0.3
UKALL14 with daSATinib - Intensification/CNS prophylaxis
311501000210103
0.0.10
UKALL14 with daSATinib - Consolidation [Cycles 1 and 2]
311511000210101
0.0.1
UKALL14 with daSATinib - Consolidation/delayed intensification [Cycle 3]
311521000210106
0.0.5
UKALL14 with daSATinib - Consolidation [Cycle 4]
311531000210108
0.0.2
UKALL14 with daSATinib - Maintenance
311541000210100
0.0.7
LEU ALL precursor B-cell BCR-ABL1+ - UKALL14 with RITUximab and daSATinib [for transplant]
components ▾
311221000210109
1.0.0
07/12/2023
Steroid pre-phase
311231000210106
0.0.5
UKALL14 with RITUximab and daSATinib [for transplant] - Phase 1 Induction
311241000210103
0.0.20
UKALL14 with RITUximab and daSATinib [for transplant] - Phase 2 Induction
311251000210100
0.0.22
UKALL14 with RITUximab and daSATinib [for transplant] - Intensification/CNS prophylaxis
311261000210102
0.0.8
UKALL14 with RITUximab and daSATinib [for transplant] - Consolidation [Cycles 1 and 2]
311271000210108
0.0.23
UKALL14 with RITUximab and daSATinib [for transplant] - Consolidation/delayed intensification [Cycle 3]
311281000210105
0.0.30
UKALL14 with RITUximab and daSATinib [for transplant] - Consolidation [Cycle 4]
311291000210107
0.0.21
LEU ALL precursor B-cell BCR-ABL1+ - UKALL14 with RITUximab and daSATinib [not for transplant]
components ▾
311421000210105
1.0.0
15/01/2024
Steroid pre-phase
311231000210106
0.0.5
UKALL14 with RITUximab and daSATinib [not for transplant] - Phase 1 Induction
311241000210103
0.0.20
UKALL14 with RITUximab and daSATinib [not for transplant] - Phase 2 Induction
311431000210107
0.0.3
UKALL14 with RITUximab and daSATinib [not for transplant] - Intensification/CNS prophylaxis
311441000210104
0.0.36
UKALL14 with RITUximab and daSATinib [not for transplant] - Consolidation [Cycles 1 and 2]
311271000210108
0.0.23
UKALL14 with RITUximab and daSATinib [not for transplant] - Consolidation/delayed intensification [Cycle 3]
311451000210101
0.0.7
UKALL14 with RITUximab and daSATinib [not for transplant] - Consolidation [Cycle 4]
311291000210107
0.0.21
UKALL14 with RITUximab and daSATinib [not for transplant] - Maintenance
311461000210103
0.0.20

UKALL60+ Regimens


Published

Name Sort
Id Sort
Version Sort
Date Sort
LEU ALL - UKALL60+ [non-intensive]
components ▾
311081000210104
1.0.0
09/11/2023
Steroid pre-phase
310981000210107
0.0.3
UKALL60+ [non-intensive] Phase 1 Induction
311091000210102
0.0.18
UKALL60+ [non-intensive] Phase 2 Induction
311101000210109
0.0.3
UKALL60+ [non-intensive] Consolidation 1
311111000210106
0.0.9
UKALL60+ [non-intensive] Maintenance
311121000210101
0.0.18
LEU ALL BCR-ABL1+ - UKALL60+ with daSATinib
components ▾
311031000210103
1.0.0
09/11/2023
Steroid pre-phase [optional]
310981000210107
0.0.3
UKALL60+ with daSATinib Phase 1 Induction
311041000210106
0.0.13
UKALL60+ with daSATinib Phase 2 Induction
311051000210109
0.0.6
UKALL60+ with daSATinib Consolidation
311061000210107
0.0.8
UKALL60+ with daSATinib Maintenance
311071000210101
0.0.19
LEU ALL BCR-ABL1+ - UKALL60+ with imatinib
components ▾
310971000210105
1.0.0
09/11/2023
Steroid pre-phase [optional]
310981000210107
0.0.3
UKALL60+ with imatinib Phase 1 Induction
310991000210109
0.0.13
UKALL60+ with imatinib Phase 2 Induction
311001000210108
0.0.10
UKALL60+ with imatinib Consolidation
311011000210105
0.0.8
UKALL60+ with imatinib Maintenance
311021000210100
0.0.17

Acute myeloid Regimens



Intensive Regimens


Published

Name Sort
Id Sort
Version Sort
Date Sort
LEU AML - 7 + 3 IDA [IDArubicin and cytarabine] induction
310951000210102
1.0.0
29/10/2023
LEU AML - ALFA 9801 [IDArubicin and cytarabine] induction
264091000210107
1.0.0
28/03/2023
LEU AML - cytarabine 1.5 g/m2 [days 1,3,5] consolidation [courses 3 and 4] [60 years and over]
60441000210108
2.0.0
29/10/2023
LEU AML - cytarabine 3 g/m2 [days 1,2,3] consolidation [courses 3 and 4] [under 60 years]
60431000210100
3.0.0
29/10/2023
LEU AML - cytarabine 3 g/m2 [days 1,3,5] consolidation [courses 3 and 4] [under 60 years]
60451000210106
2.0.0
29/10/2023
LEU AML - cytarabine 3 g/m2 [ONCE daily days 1 to 6] consolidation [courses 3 and 4]
263841000210109
2.0.0
29/10/2023
LEU AML - DA 3+10 [DAUNOrubicin and cytarabine] induction [course 1]
60461000210109
1.0.0
13/02/2023
LEU AML - DA 3+8 [DAUNOrubicin and cytarabine] induction [course 2]
60471000210103
2.0.0
29/10/2023
LEU AML - DA[45] 3+7 [DAUNOrubicin and cytarabine] induction followed by high dose cytarabine consolidation [over 60 years]
components ▾
303631000210108
1.0.0
29/10/2023
DA[45] 3+7 [DAUNOrubicin and cytarabine] induction [over 60 years]
310931000210108
0.0.11
High dose cytarabine consolidation [over 60 years]
310941000210100
0.0.14
LEU AML - DA+GO-1 [DAUNOrubicin, cytarabine and Mylotarg [gemtuzumab ozogamicin]] induction [de novo CD33+] [good or intermediate risk]
391691000210106
1.0.0
28/04/2024
LEU AML - DA+GO-2 [DAUNOrubicin, cytarabine and Mylotarg [gemtuzumab ozogamicin]] induction [de novo CD33+] [good or intermediate risk]
310961000210104
1.0.0
29/10/2023
LEU AML - DAUNOrubicin, cytarabine and midostaurin induction, high dose cytarabine and midostaurin consolidation followed by midostaurin maintenance [FLT3 mutated] [60 years and over]
components ▾
303561000210103
1.0.0
29/10/2023
DAUNOrubicin, cytarabine and midostaurin induction [60 years and over]
303571000210109
0.0.14
High dose cytarabine and midostaurin consolidation [60 years and over]
303581000210106
0.0.16
midostaurin maintenance
303591000210108
0.0.15
LEU AML - DAUNOrubicin, cytarabine and midostaurin induction, high dose cytarabine and midostaurin consolidation followed by midostaurin maintenance [FLT3 mutated] [under 60 years]
components ▾
303601000210103
1.0.0
29/10/2023
DAUNOrubicin, cytarabine and midostaurin induction [under 60 years]
303611000210101
0.0.15
High dose cytarabine and midostaurin consolidation [under 60 years]
303621000210106
0.0.13
midostaurin maintenance
303591000210108
0.0.15
LEU AML - FLAG-Ida [fludarabine, cytarabine, filgrastim and IDArubicin] [60 years and over]
60411000210107
1.0.0
19/09/2023
LEU AML - FLAG-Ida [fludarabine, cytarabine, filgrastim and IDArubicin] [under 60 years]
60421000210102
1.0.0
19/09/2023
LEU AML - MACE [amsacrine, cytarabine and etoposide]
264081000210105
2.0.0
29/08/2023
LEU AML - Manchester Protocol [mitoxantrone and cytarabine IV] induction followed by consolidation
components ▾
303531000210107
1.0.0
29/10/2023
Manchester Protocol [mitoxantrone and cytarabine IV] induction
303541000210104
0.0.14
Manchester Protocol [mitoxantrone and cytarabine IV] consolidation
303551000210101
0.0.17
LEU AML - MidAC [mitoxantrone and cytarabine]
264441000210105
2.0.0
29/08/2023
LEU AML FLT3-ITD mutated - soRAFENib maintenance after allogeneic stem cell transplant
264121000210108
1.0.0
31/03/2023
LEU AML Refractory - FLAG-Ida10 [fludarabine, cytarabine, filgrastim and IDArubicin] [under 60 years]
264141000210102
1.0.0
19/09/2023

Non-intensive Regimens


Published

Name Sort
Id Sort
Version Sort
Date Sort
LEU AML - azacitidine [7 day]
264111000210103
1.0.0
31/03/2023
LEU AML - azacitidine and venetoclax
264101000210100
1.0.0
28/03/2023
LEU AML - low dose cytarabine
60491000210104
1.0.0
13/02/2023
LEU AML - low dose cytarabine and venetoclax
60481000210101
1.0.0
13/02/2023

Relapsed Regimens


Published

Name Sort
Id Sort
Version Sort
Date Sort
LEU AML FLT3-ITD mutated Relapsed - azacitidine and soRAFENib
264131000210105
1.0.0
31/03/2023
LEU AML Relapsed - FLAG [fludarabine, cytarabine and filgrastim] [60 years and over]
263981000210108
1.0.0
19/09/2023
LEU AML Relapsed - FLAG [fludarabine, cytarabine and filgrastim] [under 60 years]
263861000210105
1.0.0
19/09/2023
LEU AML Relapsed - FLAG-amsacrine [fludarabine, cytarabine, filgrastim and amsacrine] [60 years and over]
263871000210104
1.0.0
19/09/2023
LEU AML Relapsed - FLAG-amsacrine [fludarabine, cytarabine, filgrastim and amsacrine] [under 60 years]
263881000210102
1.0.0
19/09/2023
LEU AML Relapsed - gilteritinib [FLT3 mutated]
264151000210104
1.0.0
31/03/2023

Acute promyelocytic Regimens


Published

Name Sort
Id Sort
Version Sort
Date Sort
LEU APL - AIDA induction and consolidations 1, 2 and 3 [70 years and under]
components ▾
311841000210102
1.0.0
19/02/2024
AIDA [70 years and under] - Induction
311851000210104
0.0.32
AIDA [70 years and under] - Consolidation 1
311861000210101
0.0.22
AIDA [70 years and under] - Consolidation 2
311871000210107
0.0.19
AIDA [70 years and under] - Consolidation 3
311881000210109
0.0.16
LEU APL - AIDA induction and consolidations 1, 2 and 3 [over 70 years]
components ▾
391701000210106
1.0.0
28/04/2024
AIDA [over 70 years] - Induction
391711000210108
0.0.7
AIDA [over 70 years] - Consolidation 1
391721000210103
0.0.4
AIDA [over 70 years] - Consolidation 2
391731000210101
0.0.5
AIDA [over 70 years] - Consolidation 3
391741000210109
0.0.5
LEU APL - APML4 induction, consolidation 1 and 2 followed by maintenance [60 years and under]
components ▾
311551000210102
1.0.0
22/01/2024
APML4 [60 years and under] - Induction
311561000210104
0.0.27
APML4 [60 years and under] - Consolidation 1
311571000210105
0.0.22
APML4 [60 years and under] - Consolidation 2
311581000210107
0.0.27
APML4 [60 years and under] - Maintenance
311591000210109
0.0.6
LEU APL - APML4 induction, consolidation 1 and 2 followed by maintenance [61 to 70 years]
components ▾
311761000210109
1.0.0
28/01/2024
APML4 [61 to 70 years] - Induction
311771000210103
0.0.4
APML4 [61 to 70 years] - Consolidation 1
311781000210101
0.0.5
APML4 [61 to 70 years] - Consolidation 2
311791000210104
0.0.7
APML4 [61 to 70 years] - Maintenance
311801000210100
0.0.3
LEU APL - APML4 induction, consolidation 1 and 2 followed by maintenance [over 70 years]
components ▾
311701000210105
1.0.0
28/01/2024
APML4 [over 70 years] - Induction
311711000210107
0.0.3
APML4 [over 70 years] - Consolidation 1
311721000210102
0.0.3
APML4 [over 70 years] - Consolidation 2
311741000210108
0.0.6
APML4 [over 70 years] - Maintenance
311751000210106
0.0.22
LEU APL - arsenic trioxide and tretinoin induction followed by consolidation [AML17]
components ▾
311811000210103
1.0.0
28/01/2024
arsenic trioxide and tretinoin [AML17] - Induction
311821000210108
0.0.32
arsenic trioxide and tretinoin [AML17] - Consolidation
311831000210105
0.0.23
LEU APL - arsenic trioxide, tretinoin and prEDNISone induction followed by consolidation [standard risk]
components ▾
311601000210104
1.0.0
22/01/2024
arsenic trioxide, tretinoin and prEDNISone [standard risk] - Induction
311611000210102
0.0.22
arsenic trioxide and tretinoin [standard risk] - Consolidation
311621000210107
0.0.21
LEU APL - Pethema LPA2005 induction and consolidations 1, 2 and 3 followed by maintenance [60 to 70 years] [high risk]
components ▾
312571000210101
1.0.0
28/04/2024
Pethema LPA2005 [60 to 70 years] [high risk] - Induction
312581000210104
0.0.8
Pethema LPA2005 [60 to 70 years] [high risk] - Consolidation 1
312591000210102
0.0.6
Pethema LPA2005 [60 to 70 years] [high risk] - Consolidation 2
312601000210107
0.0.6
Pethema LPA2005 [60 to 70 years] [high risk] - Consolidation 3
312611000210109
0.0.5
Pethema LPA2005 [60 to 70 years] [high risk] - Maintenance
312621000210104
0.0.6
LEU APL - Pethema LPA2005 induction and consolidations 1, 2 and 3 followed by maintenance [70 years and under] [intermediate risk]
components ▾
311641000210101
2.0.0
28/04/2024
Pethema LPA2005 [70 years and under] [intermediate risk] - Induction
311651000210103
0.0.6
Pethema LPA2005 [70 years and under] [intermediate risk] - Consolidation 1
311661000210100
0.0.4
Pethema LPA2005 [70 years and under] [intermediate risk] - Consolidation 2
311671000210106
0.0.4
Pethema LPA2005 [70 years and under] [intermediate risk] - Consolidation 3
311681000210108
0.0.4
Pethema LPA2005 [70 years and under] [intermediate risk] - Maintenance
311691000210105
0.0.4
LEU APL - Pethema LPA2005 induction and consolidations 1, 2 and 3 followed by maintenance [70 years and under] [low risk]
components ▾
391591000210105
1.0.0
28/04/2024
Pethema LPA2005 [70 years and under] [low risk] - Induction
391601000210100
0.0.7
Pethema LPA2005 [70 years and under] [low risk] - Consolidation 1
391621000210108
0.0.3
Pethema LPA2005 [70 years and under] [low risk] - Consolidation 2
391661000210101
0.0.4
Pethema LPA2005 [70 years and under] [low risk]- Consolidation 3
391671000210107
0.0.3
Pethema LPA2005 [70 years and under] [low risk] - Maintenance
391681000210109
0.0.4
LEU APL - Pethema LPA2005 induction and consolidations 1, 2 and 3 followed by maintenance [over 70 years] [high risk]
components ▾
391471000210105
1.0.0
28/04/2024
Pethema LPA2005 [over 70 years] [high risk] - Induction
391481000210107
0.0.7
Pethema LPA2005 [over 70 years] [high risk] - Consolidation 1
391491000210109
0.0.4
Pethema LPA2005 [over 70 years] [high risk] - Consolidation 2
391501000210104
0.0.6
Pethema LPA2005 [over 70 years] [high risk] - Consolidation 3
391511000210102
0.0.5
Pethema LPA2005 [over 70 years] [high risk] - Maintenance
391521000210107
0.0.5
LEU APL - Pethema LPA2005 induction and consolidations 1, 2 and 3 followed by maintenance [over 70 years] [intermediate risk]
components ▾
312701000210101
1.0.0
28/04/2024
Pethema LPA2005 [over 70 years] [intermediate risk] - Induction
312711000210104
0.0.7
Pethema LPA2005 [over 70 years] [intermediate risk] - Consolidation 1
312721000210109
0.0.4
Pethema LPA2005 [over 70 years] [intermediate risk] - Consolidation 2
312731000210106
0.0.5
Pethema LPA2005 [over 70 years] [intermediate risk] - Consolidation 3
312741000210103
0.0.3
Pethema LPA2005 [over 70 years] [intermediate risk] - Maintenance
391411000210101
0.0.4
LEU APL - Pethema LPA2005 induction and consolidations 1, 2 and 3 followed by maintenance [over 70 years] [low risk]
components ▾
391531000210109
1.0.0
28/04/2024
Pethema LPA2005 [over 70 years] [low risk] - Induction
391541000210101
0.0.6
Pethema LPA2005 [over 70 years] [low risk] - Consolidation 1
391551000210103
0.0.4
Pethema LPA2005 [over 70 years] [low risk] - Consolidation 2
391561000210100
0.0.4
Pethema LPA2005 [over 70 years] [low risk] - Consolidation 3
391571000210106
0.0.3
Pethema LPA2005 [over 70 years] [low risk] - Maintenance
391581000210108
0.0.4
LEU APL - Pethema LPA2005 induction and consolidations 1, 2 and 3 followed by maintenance [under 60 years] [high risk]
components ▾
312631000210102
1.0.0
28/04/2024
Pethema LPA2005 [under 60 years] [high risk] - Induction
312651000210108
0.0.25
Pethema LPA2005 [under 60 years] [high risk] - Consolidation 1
312661000210106
0.0.18
Pethema LPA2005 [under 60 years] [high risk] - Consolidation 2
312671000210100
0.0.17
Pethema LPA2005 [under 60 years] [high risk] - Consolidation 3
312681000210103
0.0.16
Pethema LPA2005 [under 60 years] [high risk] - Maintenance
312691000210101
0.0.20

Chronic lymphocytic Regimens


Published

Name Sort
Id Sort
Version Sort
Date Sort
LEU CLL - acalabrutinib
264431000210102
1.0.0
19/09/2023
LEU CLL - chlorambucil
60141000210100
1.0.0
15/12/2022
LEU CLL - chlorambucil [flat dosing]
60131000210108
1.0.0
15/12/2022
LEU CLL - chlorambucil and oBINUTUZumab
264411000210109
1.0.0
19/09/2023
LEU CLL - FCR [fludarabine, CYCLOPHOSPHamide and RITUximab] [oral] [3 day]
264851000210105
1.0.0
21/07/2023
LEU CLL - FCR [fludarabine, CYCLOPHOSPHamide and RITUximab] [oral] [5 day]
264841000210107
1.0.0
21/07/2023
LEU CLL - FCR [IV] fludarabine, CYCLOPHOSPHamide and RITUximab
264831000210104
1.0.0
21/07/2023
LEU CLL - ibrutinib
60151000210102
1.0.0
19/09/2023
LEU CLL - RITUximab and bendamustine
311311000210108
1.0.0
21/12/2023
LEU CLL - venetoclax
264821000210101
1.0.0
21/07/2023
LEU CLL - venetoclax and oBINUTUZumab
311321000210103
1.0.0
21/12/2023
LEU CLL - venetoclax and RITUximab
311171000210102
1.0.0
30/11/2023
LEU CLL Relapsed - aLEMTUzumab [IV]
311301000210106
1.0.0
21/12/2023
LEU CLL Relapsed - aLEMTUzumab [subcut]
311331000210101
1.0.0
24/12/2023

Chronic myeloid Regimens


Published

Name Sort
Id Sort
Version Sort
Date Sort
LEU CML - daSATinib
components ▾
264791000210105
1.0.0
21/07/2023
daSATinib 100
264801000210109
0.0.8
daSATinib 140
264811000210106
0.0.13
LEU CML - imatinib
components ▾
311141000210107
1.0.0
30/11/2023
imatinib 400
311151000210105
0.0.11
imatinib 600
311161000210108
0.0.17
LEU CML - nilotinib
components ▾
264381000210107
1.0.0
25/05/2023
nilotinib 400
264391000210109
0.0.11
nilotinib 300
264401000210107
0.0.8
LEU CML - pONATinib
264941000210104
1.0.0
04/08/2023

Chronic myelomonocytic Regimens


Published

Name
Id
Version
Date
LEU CMML - azacitidine [7 day]
263851000210107
1.0.0
28/03/2023

Hairy cell Regimens


Published

Name Sort
Id Sort
Version Sort
Date Sort
LEU HCL - cladribine
264781000210108
1.0.0
21/07/2023
LEU HCL - cladribine and RITUximab
311631000210109
1.0.0
28/01/2024
LEU HCL - RITUximab
264881000210100
1.0.0
19/09/2023

Myelodysplastic syndrome Regimens


Published

Name Sort
Id Sort
Version Sort
Date Sort
Myelodysplastic syndrome - azacitidine [5 day]
263991000210105
1.0.0
28/03/2023
Myelodysplastic syndrome - azacitidine [7 day]
264001000210101
1.0.0
28/03/2023

Myeloproliferative neoplasm Regimens


Published

Name Sort
Id Sort
Version Sort
Date Sort
MPN - busulfan
60241000210109
1.0.0
21/12/2022
MPN Myelofibrosis - ruxolitinib
264891000210103
1.0.0
23/07/2023

T-cell prolymphocytic Regimens


Published

Name Sort
Id Sort
Version Sort
Date Sort
LEU T-PLL - aLEMTUzumab [IV]
264861000210108
2.0.0
24/12/2023
LEU T-PLL Relapsed - pentostatin
264871000210102
1.0.0
23/07/2023